000403.SZ
派林生物
SZSE · Healthcare · C 制造业 · CN
CNY 10.26
−3.48%Aug 23, 2026, 13:25 UTC
Pailin Biologics reported its 2026 first-half results on August 23, with net profit attributable to shareholders down 64.25% year-on-year to 84.301 million yuan and revenue down 15.88% to 830 million yuan.
Aug 23, 2026, 13:25 UTC
Pailin Biologics proposed a cash dividend of 1.5 yuan per 10 shares (tax included) for the first half of 2026.